Oncternal Therapeutics Inc
NASDAQ:ONCT
Relative Value
The Relative Value of one ONCT stock under the Base Case scenario is 3.25 USD. Compared to the current market price of 8.48 USD, Oncternal Therapeutics Inc is Overvalued by 62%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
ONCT Competitors Multiples
Oncternal Therapeutics Inc Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
US |
Oncternal Therapeutics Inc
NASDAQ:ONCT
|
25m USD | 31.8 | -0.6 | 0.2 | 0.2 | ||
US |
Abbvie Inc
NYSE:ABBV
|
285.2B USD | 5.3 | 59.2 | 12.9 | 19.6 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
148B USD | 5.2 | 22 | 16.4 | 24.5 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
102.1B USD | 10.3 | 28.2 | 22.5 | 23.6 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
97.6B USD | 7.4 | 24.7 | 16.3 | 17.9 | ||
AU |
CSL Ltd
ASX:CSL
|
132.9B AUD | 6.2 | 35.3 | 21.4 | 26.5 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
82.2B USD | 3 | 14.5 | 8 | 10.3 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
42.6B USD | 6.2 | -9 | -9.6 | -8.2 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
31.2B USD | 3.2 | 26.9 | 14.5 | 18 | ||
KR |
Celltrion Inc
KRX:068270
|
39.3T KRW | 18.1 | 73.5 | 45 | 61.9 |